But here is the reality: as of April 2026, no GLP-1 patch is FDA-approved or commercially available
When tissues such as muscle, liver, and fat no longer respond effectively to insulin, glucose remains in the bloodstream, increasing the risk of type 2 diabetes, obesity, and cardiovascular disease. This connection between estrogen and insulin resistance has sparked interest in how hormone replacement therapy (HRT) may work synergistically with modern weight loss therapies, particularly glucagon-like GLP-1 receptor agonists and glucose-dependent insulin tropic polypeptide (GIP) receptor/GLP-1 receptor agonist combos
Vitamin C transport and its role in the central nervous system
May also aid in the treatment of obesity and chronic weight management in adjunction to a reduced calorie diet and increased physical activity
HUBERMAN: Now, when we say positive effects, we have to stand back and say, well, what's the control experiment